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Abstract
Background: Chronic mucus hypersecretion (CMH) is associated with an increased frequency of respiratory infections, excess
lung function decline, and increased hospitalisation and mortality rates in the general population. It is associated with smoking,
but it is unknown why only a minority of smokers develops CMH. A plausible explanation for this phenomenon is a predisposing
genetic constitution. Therefore, we performed a genome wide association (GWA) study of CMH in Caucasian populations.
Methods: GWA analysis was performed in the NELSON-study using the Illumina 610 array, followed by replication and meta-
analysis in 11 additional cohorts. In total 2,704 subjects with, and 7,624 subjects without CMH were included, all current or
former heavy smokers ($20 pack-years). Additional studies were performed to test the functional relevance of the most
significant single nucleotide polymorphism (SNP).
Results: A strong association with CMH, consistent across all cohorts, was observed with rs6577641 (p = 4.2561026,
OR = 1.17), located in intron 9 of the special AT-rich sequence-binding protein 1 locus (SATB1) on chromosome 3. The risk allele
(G) was associated with higher mRNA expression of SATB1 (4.361029) in lung tissue. Presence of CMH was associated with
increased SATB1 mRNA expression in bronchial biopsies from COPD patients. SATB1 expression was induced during
differentiation of primary human bronchial epithelial cells in culture.
Conclusions: Our findings, that SNP rs6577641 is associated with CMH in multiple cohorts and is a cis-eQTL for SATB1,
together with our additional observation that SATB1 expression increases during epithelial differentiation provide
suggestive evidence that SATB1 is a gene that affects CMH.
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Introduction
The secretion of mucus is a natural part of the airway defense
against inhaled noxious particles and substances. Chronic mucus
hypersecretion (CMH) is a condition of overproduction of mucus
and defined as the presence of sputum production during at least
three months in two consecutive years without any explaining
origin whereas airway obstruction is not a prerequisite [1].
Smoking is a risk factor for CMH, i.e. the prevalence of CMH in
the general population is reported to be 7.4% in current smokers,
3.7% in ex-smokers and 2.4% in never smokers [2]. CMH is the
key presenting symptom in chronic bronchitis, one of the three
main sub-groups of chronic obstructive pulmonary disease
(COPD), a complex disease characterized by the presence of
incompletely reversible and generally progressive airflow limitation
[3]. Moreover, CMH is a risk factor for the development of
COPD [4,5].
Worldwide, COPD affected 65 million people in 2004 and
more than 3 million people died of COPD in 2005, representing
5% of all deaths. It is predicted that COPD will be the third
leading cause of death worldwide in 2030 [6]. COPD markedly
reduces quality of life and is responsible for high healthcare costs.
For instance, the combined (direct and indirect) yearly costs of
COPD and asthma in the United States of America were
projected at $68 billion in 2008 [7]. CMH is not only associated
with COPD but also with an increased duration and frequency of
respiratory infections, excess decline in forced expiratory volume
in 1 second (FEV1) and increased hospitalization and mortality
rates in the general population [4,5,8,9].
It is not known why only a minority of all smokers develops
CMH, yet a plausible explanation is the presence of a genetic
predisposition for CMH, as evidenced by familial aggregation of
mucus overproduction and higher prevalence of CMH in
monozygotic than in dizygotic twins [10–12]. Little is known
about the identity of the genes that predispose to CMH. One
publication suggested that CTLA4 is associated with chronic
bronchitis in COPD [13].
The aim of our study was to identify genetic factors for CMH,
thereby obtaining a better insight into the origins of this disorder.
Genetic Influence of SATB1 on Airway Disease
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Materials and Methods
Ethics Statement
The Dutch ministry of health and the Medical Ethics
Committee of the hospital approved the study protocol for all
Dutch centers. Ethics approval and written informed consent was
obtained from all participants in all studies participating. For
detailed information, see Supplement S1.
Subjects and genotyping
We performed GWA studies in participants of the NELSON-
study (n = 3,729), a male population-based lung cancer screening
study investigating heavy smokers ($20 pack-years) [24].
Replication of SNPs with p#1024 was attempted in six cohorts
participating in ‘COPD Pathology: Addressing Critical gaps, Early
Treatment & diagnosis and Innovative Concepts’ (COPACETIC)
and in five non-COPACETIC cohorts. Caucasian subjects with
$20 pack-years smoking with genotype-, spirometric- and
demographic data were included.
An overview of the CMH definitions used in this study is
presented in Table 1. A brief description of the included cohorts
and details according to the period of data collection, type of
population, genotyping platforms and genetic imputation software
are presented in in Table 2.
Table 1. Questions used to define chronic mucus hypersecretion in the corresponding cohorts.
Cohort Question
NELSON [24] Do you expectorate sputum on the majority of days more than 3 months a year, even when you do not have a cold?
Rotterdam [25,26] Do you expectorate sputum on the majority of days during $3 months during the last 2 years?
LifeLines [27] Do you usually expectorate sputum during day or night in winter? If yes: Do you expectorate sputum on the majority of days
.3 months a year?
Vlagtwedde- Vlaardingen [28,29] Do you expectorate sputum on the majority of days .3 months a year?
Doetinchem [30] Do you expectorate sputum during winter, day and night, each day for 3 months?
Poland [31,32] Do you usually bring up phlegm from your chest, or do you usually have phlegm in your chest that is difficult to bring up when
you don’t have a cold? If yes: Are there months in which you have this phlegm on most days? If yes: Do you bring up this
phlegm on most days for as much as three months each year? A positive answer to all (3) questions identifies CMH.
Heidelberg [33] Do you expectorate sputum on the majority of days .3 months a year?
GLUCOLD [15] Do you expectorate sputum immediately after getting up on the majority of days in winter .3 months a year?
Rucphen [29] Do you expectorate sputum during day or night in winter? If yes: Do you have expectoration on the majority of days .3
months a year?
ECLIPSE [34] Do you usually bring up phlegm from your chest on getting up, first thing in the morning, during the rest of the day or at night,
on most days for 3 consecutive months or more during the year?
COPDGene [35] Do you usually bring up phlegm from your chest on getting up, first thing in the morning, during the rest of the day or at night,
on most days for 3 consecutive months or more during the year?
Norway [36,37] Do you usually bring up phlegm from your chest on getting up, first thing in the morning, during the rest of the day or at night,
on most days for 3 consecutive months or more during the year?
doi:10.1371/journal.pone.0091621.t001
Table 2. Overview of populations.
Study Data Collection Type of population Genotyping platform Imputation software
NELSON 2004/2005 general population Illumina Quad 610 NA
GLUCOLD 2005/2006 COPD case Illumina Veracode NA
Vlagtwedde Vlaardingen 1989/1990 general population Illumina Veracode NA
Doetinchem 1998/2002 general population Illumina Veracode NA
Poland 2005/2006 general population Illumina Veracode NA
Heidelberg 2004/2005 general population Illumina Veracode NA
Rucphen 2002 Family based COPD on a doctor
diagnosis
Illumina Veracode NA
Rotterdam 2002/2008 general population Illumina 550K MaCH
LifeLines 2008/2010 general population Illumina Human CytoSNP-12 BEAGLE v3.1.0
COPDGene 2008/2009 COPD case/control (stage I–IV) Illumina Human Omni1-Quad MaCH
ECLIPSE 2005/2007 COPD case/control (stage II–IV) Illumina Human HAP 550 V3 MaCH
Norway 2003/2005 COPD case/control (stage II–IV) Illumina Human HAP 550 V1, V3,
and DUO
MaCH
Populations and corresponding period of data collection, type of population, genotyping platform and soft-ware used for imputation.
NA= not applicable.
doi:10.1371/journal.pone.0091621.t002
Genetic Influence of SATB1 on Airway Disease
PLOS ONE | www.plosone.org 3 April 2014 | Volume 9 | Issue 4 | e91621
Strategy
We searched for SNPs associated with CMH by using a two-
stage strategy followed by a replication stage and meta-analysis
(Figure 1).
Statistical analysis
General characteristics of CMH-cases and controls were
compared using Student’s t- and Mann-Whitney-U tests for
continuous variables and x2 tests for dichotomous variables with
SPSS 20.0. Sample and SNP quality control (QC), regression- and
meta-analysis were performed with PLINK 1.07 [25]. QC criteria
are described in Supplement S1.
Logistic regression analysis under an additive model was used to
identify SNPs associated with CMH. SNPs with a p-value,1024
were included for replication. When two SNPs were in strong
linkage disequilibrium (r2$0.8), the SNP with the lowest p-value
was further analyzed.
SNPs in COPACETIC cohorts and in LifeLines were analyzed
using logistic regression with adjustment for sex and smoking (ex-/
current smoking). In LifeLines, imputed SNPs with an info-score
,0.3 (imputation quality score) were removed. SNPs in non-
COPACETIC cohorts were analyzed by the cohort investigators
using the same model.
Meta-analysis was performed on SNPs across NELSON and the
11 replication cohorts. The Cochran’s Q test was used to test for
heterogeneity in the meta-analysis.
We performed multivariate logistic regression analysis, adjusted
for pack-years and lung function, to associate CMH with the risk
allele of rs6577641 in the identification cohort.
Functional relevance of SATB1 and rs6577641, our
highest ranked-SNP
We performed 4 functional studies with the identified top-SNP.
Details on their methods are given in Supplement S1.
We assessed:
1) whether rs6577641 is an eQTL, by analyzing the association
of SATB1 expression levels with rs6577641 genotypes in lung
tissue from three independent cohorts recruited from Laval
University, University of British Columbia, and University of
Groningen as described previously [14];
2) CMH-associated mRNA expression in airway wall biopsies
from 77 COPD participants in the GLUCOLD-study [15];
3) the association of homozygous genotypes for rs6577641 with
a) immunohistochemical staining (IHC) for SATB1 and b) the
fraction of mucus positivity on bronchial tissue explanted from
COPD or lung cancer subjects that underwent lung surgery;
4) SATB1 expression levels during mucociliary differentiation of
primary bronchial epithelial cells cultured at air-liquid
interface [26].
Results
Populations
Characteristics of the identification and replication populations
are presented in Table 3. Subjects with CMH were more often
current smokers and had worse lung function, except for
populations including subjects with COPD only.
Identification analysis
After QC, 492,700 SNPs and 2,512 individuals (717 CMH
cases, 1,795 controls) from the NELSON study remained. Logistic
regression analysis was performed including these individuals
Figure 1. Study design. We performed GWA studies in the NELSON cohort and in additional healthy controls. CMH was analyzed using logistic
regression with adjustment for center (Groningen and Utrecht). Since current smoking can affect the presence of CMH, we additionally performed the
GWAS in the NELSON cohort correcting for center and smoking. SNPs with a p-value,10-4 present in both GWA studies were selected for replication.
To test for generalizability of associations with CMH in other populations, we compared our results with data in CMH-cases and controls with a
smoking history of$20 pack-years with eleven replication populations using logistic regression with adjustment for sex and current smoking. Finally,
we performed a meta-analysis on shared SNPs across the NELSON identification population and the 11 replication populations.
doi:10.1371/journal.pone.0091621.g001
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supplemented with 590 additional healthy controls, adjusting for
center. The QQ-plot provided no evidence of population
stratification (l=1.0185). 77 SNPs were associated with CMH
with a p-value,1024. CMH was associated with current smoking
in our identification cohort (p,0.001). Therefore, we performed a
second GWA adjusting for center and current/ex-smoking (717
CMH-cases, 1,795 controls). The QQ-plot showed no evidence of
population stratification (l=1.0056). We observed 64 SNPs with a
p-value,1024. Genome wide association for CMH ordered by
chromosome is shown in the Manhattan plot. Figure 2 shows QQ-
plots (A, C) and genome wide association signals for CMH ordered
by chromosome (Manhattan-plots, B and D) of these sequential
analyses. We identified 36 SNPs associated with CMH with a p-
value,1024 in both analyses Table 4. Of these, 32 SNPs were
included for replication and 4 SNPs were removed because they
were in strong linkage disequilibrium (r2.0.8) with another
associated SNP.
Replication of associated SNPs
Genotyping of SNP rs4775569 failed in the COPACETIC
populations, and was removed for further analysis. CMH-
associated top-SNPs for each cohort are presented in Table 5,
with a complete overview in Table 6. When applying Bonferroni
correction in the meta-analysis (p = 1.6161023 for 31 SNPs), we
found a strong association with one SNP:
N rs6577641, a SNP located on chromosome 3 in intron 9 of the
special AT-rich sequence-binding protein 1 locus (SATB1) (combined
p-value = 4.2561026, OR=1.17; 1.10–1.26).
The SATB1 SNP rs6577641 had the lowest p-value for
association with CMH in the meta-analysis. Figure 3 shows the
forest plot of rs6577641 in the identification and replication
cohorts and meta-analysis.
We assessed the percentage of subjects with CMH in each
genotyping group for rs6577641 in NELSON-total and stratified
for current and ex smokers (Figure 4). Multivariate logistic
regression analysis, corrected for pack-years and FEV1%predicted,
showed that CMH was significantly associated with the number of
G-alleles in the 1,385 current smokers (reference =AA: heterozy-
gous mutant (AG) p= 0.001; OR=1.50, homozygous mutant
(GG) p= 0.001; OR=1.80) but not in 1,127 ex-smokers (refer-
ence =AA: heterozygous mutant (AG) p= 0.380; OR=1.18,
homozygous mutant (GG) p= 0.143; OR=1.42).
Table 3. Demographic and clinical characteristics of CMH-cases and -controls with $20 pack-years, present in the meta-analysis.
Population CMH N Population % Female, %
Age, yrs
(SD)
Pack-years
(range)
Current
smoking, %
FEV1 %,
pred. (SD) FEV1/FVC, % (SD)
NELSON Control 1,795 71.5 0 60.2 (5.3) 34 (21–156) 47.5 100.3 (17.2) 72.9 (8.7)
NELSON Case 717 28.5 0 60.4 (5.6) 39 (21–140) 74.2 93.5 (20.0) 69.2 (11.0)
Rotterdam Control 1,043 84.1 46.1 68.0 (9.3) 45 (20–149) 40.1 92.4 (23.5)# 72.8 (8.7)#
Rotterdam Case 197 15.9 43.7 72.0 (8.4) 40 (20–168) 45.2 85.0 (26.9)# 68.0 (11.1)#
LifeLines Control 1,431 88.1 80.1 52.9 (9.2) 27 (20–100) 56.4 98.2 (15.6) 72.4 (8.2)
LifeLines Case 193 11.5 46.9 53.2 (9.9) 29 (20–97) 75.4 90.5 (18.0) 68.3 (11.3)
Vlagtwedde-
Vlaardingen*
Control 234 82.4 27.4 52.9 (10.1) 29 (20–128) 51.7 94.5 (12.1) 76.6 (4.5)
Vlagtwedde-
Vlaardingen*
Case 50 17.6 18 53.4 (10.5) 33 (22–83) 68 86.7 (18.6) 71.0 (8.9)
Doetinchem Control 250 80.6 37.2 54.7 (8.8) 30 (20–90) 55.6 94.8 (17.6) 71.5 (9.9)
Doetinchem Case 60 19.4 36.7 56.4 (7.7) 33 (20–72) 68.3 89.1 (19.6) 69.3 (11.4)
Poland Control 97 85.1 22.7 56.7 (10.5) 30 (20–116) 52.6 96.4 (21.4) 72.5 (0.5)
Poland Case 17 14.9 11.8 55.8 (9.4) 35 (22–86) 82.4 93.5 (24.0) 69.2 (13.1)
Heidelberg Control 608 84.2 35.7 58.1 (5.2) 37 (23–138) 54.3 96.4 (17.6) 78.9 (9.7)
Heidelberg Case 114 15.8 29.8 58.0 (5.2) 37 (23–91) 91.2 86.2 (21.5) 75.3 (10.6)
GLUCOLD** Control 48 55.2 8.3 62.6 (7.6) 46 (21–182) 62.5 63.4 (9.8) 50.4 (9.1)
GLUCOLD** Case 39 44.8 20.5 59.6 (7.4) 40 (22–83) 61.5 63.9 (8.8) 53.1 (7.8)
Rucphen** Control 28 53.8 46.4 66.5 (7.9) 42 (21–120) 57.1 74.5 (15.7) 57.2 (7.8)
Rucphen** Case 24 46.2 41.7 62.2 (10.5) 43 (21–100) 70.8 70.2 (21.6) 53.1 (9.7)
ECLIPSE** Control 961 62 37.5 64.1 (6.7) 53 (21–205) 28.1 48.0 (15.7) 44.5 (11.3)
ECLIPSE** Case 590 38 24.1 62.9 (7.4) 54 (22–220) 47.5 46.2 (15.5) 44.3 (11.7)
COPDGene Control 628 71.8 53.5 63.1 (8.6) 50 (21–173) 28.2 75.0 (28.3) 63.7 (17.6)
COPDGene Case 247 28.2 40.5 61.9 (8.4) 54 (21–237) 50.2 60.4 (27.4) 54.6 (17.9)
Norway Control 501 52.4 44.9 61.5 (10.3) 34 (20–130) 46.9 71.7 (24.2) 64.6 (15.7)
Norway Case 456 47.6 20.4 64.1 (10.1) 39 (20–119) 59 56.5 (24.4) 55.0 (17.3)
CMH=Chronic mucus hypersecretion;
*lung function is based on FEV1/IVC;
**all individuals in this cohort have COPD;
#based on lung function of 700 subjects who returned for follow-up study 4 years later.
doi:10.1371/journal.pone.0091621.t003
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Functional relevance of SATB1 and rs6577641
1) Transcriptional regulation of SATB1 mRNA expression
We analyzed the association of SATB1 expression levels in lung
tissue with rs6577641 genotype in 3 independent data sets of the
Universities of Groningen, Laval and UBC [14]. A cis-acting effect
of rs6577641 on SATB1 expression was identified and present in
all three datasets (n = 1,095), with the same direction of effect
across all three SATB1 probes on the array. The (susceptibility) G
allele increased expression, the (protective) A allele reduced
expression (p = 4.361029) in the meta-analysis across the three
datasets and across all three SATB1 probes measured (Table 7).
2) SATB1 mRNA expression and CMH
We compared SATB1 expression in baseline airway wall
biopsies of COPD patients with (n = 38) and without (n = 39)
CMH in GLUCOLD [15]. CMH was significantly associated with
SATB1 expression levels (corrected for ex-/current smoking;
p = 0.0045; Figure 5). After stratification, the same direction of
effect was present in ex- and current smokers. However, this
association reached statistical significance in current smokers
(p = 0.021) and not in ex- smokers (p = 0.132), probably due to a
difference in power as 46 subjects were current smokers versus 33
ex-smokers.
3) Genotype related protein expression and mucus positivity in
bronchial epithelium
SATB1 protein expression has previously been observed in IHS
analysis of bronchial epithelial cells [16]. Therefore, we stained
SATB1 on paraffin embedded lung tissue biopsies of individuals
from the Groningen population contributing to the eQTL
analysis. We observed clear nuclear staining for SATB1 in
bronchial epithelial cells. No significant difference for % of strong
positive, positive and weak positive cells was observed between the
protective (AA, n= 9) and risk (GG, n= 14) rs6577641 genotypes
(11.8%65.8 versus 12.7%66.9, p = 0.74).
We determined whether the fraction of mucus positive
bronchial epithelium was different in subjects with different
homozygous rs6577641 genotypes and performed PAS-staining
on tissue biopsies from the same cohort. We observed no
significant difference between individuals with the homozygous
protective (AA, n= 10) and risk (GG, n= 7) alleles (19.7%611.9
versus 14.3%69.6, p= 0.34).
4) SATB1 expression levels during bronchial epithelial cell
mucociliary differentiation
We investigated whether SATB1 expression was induced during
mucociliary differentiation of primary human bronchial epithelial
Figure 2. Quantile-quantile plot and Manhattan plot of GWA results for association of SNPs with CMH in NELSON amplified with
bloodbank controls and corrected for center (A and B). Quantile-quantile plot and Manhattan plot of GWA results for association of SNPs with
CMH in NELSON, corrected for center and smoking habits (C and D).
doi:10.1371/journal.pone.0091621.g002
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(HBE) cells in vitro and compared SATB1 mRNA expression levels
at different time points of an air-liquid interface (ALI) culture for
up to 45 days. ALI culture of HBE cells induced mucociliary
differentiation, as confirmed by induction of expression of FOXJ1,
a marker for ciliated cells (19) and MUC5AC, a marker of goblet
cells. SATB1 expression was induced over time (Figure 6), with an
approximately 8-fold increased expression from the start to the
end of the 45-day ALI culture period.
Discussion
Since not every ex- or current heavy smoker suffers from
chronic mucus hypersecretion (CMH), we aimed to identify
genetic variants conferring susceptibility to CMH. Therefore, we
performed the first GWA study on CMH, the key presenting
symptom in chronic bronchitis. CMH was associated with 36
SNPs at the p,1024 significance level in the identification cohort.
In the meta-analysis combining our identification and replication
cohorts, strong association was observed with rs6577641, a SNP
located on chromosome 3 in intron 9 of SATB1. Although the
association of rs6577641 with CMH did not reach conventional
genome-wide significance, its effect was in the same direction and
was significant (4.2561026) at nominal levels (1.6161023) across
eleven study populations, showing the robustness of this finding.
The detected odds ratio for this SNP suggests an additional risk of
Table 4. SNPs associated with CMH with a p-value,1024, present in GWAS-I and in GWAS-II, in the NELSON identification cohort.
Chromosome SNP Base pair position p-value GWAS I p-value GWAS II
2 rs6735868 103582093 1.11610205 1.08610205
3 rs1387089 1940922 7.94610205 4.56610205
3 rs1488757 1981567 2.17610205 1.16610205
3 rs6577641 18397849 6.83610205 2.57610205
4 rs4306981 79924121 9.74610205 5.18610205
8 rs4242562 115475287 7.66610205 5.13610205
8 rs7836298 115504434 1.03610205 4.37610206
8 rs7823554* 115553109 6.05610205 5.22610205
8 rs7836963* 115568426 5.52610205 4.24610205
8 rs16886291 115711436 3.54610205 2.09610205
8 rs10098746 125838127 8.47610205 4.34610205
8 rs7831595 144974963 3.08610205 2.32610205
9 rs4842047 138816796 2.63610205 4.51610205
10 rs943189 22842590 5.57610205 6.33610205
11 rs11026531 22379184 2.76610205 8.55610205
12 rs1894307* 12005720 9.04610206 7.18610206
12 rs2255953 12010736 1.13610205 4.33610206
12 rs2855708 12013572 6.47610205 3.97610205
12 rs10879509* 73242131 6.98610206 4.44610205
12 rs4760851 73284781 4.85610206 2.29610205
12 rs952394 73441110 4.18610205 4.22610205
12 rs12822199 75458164 4.82610205 8.58610205
12 rs1379963 75493882 1.18610205 2.20610205
12 rs1795669 76273692 8.01610205 7.86610205
13 rs9578362 21882381 4.28610205 7.99610205
13 rs1211304 50381016 9.96610205 1.12610205
14 rs992745 27810095 7.67610205 2.99610205
15 rs754661 26934277 4.54610205 2.88610205
15 rs4775569 46850317 4.20610205 1.72610205
16 rs13333521 19904082 5.08610205 2.50610205
17 rs11652469 49565797 1.13610205 3.80610205
18 rs8086262 69227590 1.15610205 2.53610205
20 rs4815628 3891896 4.17610205 2.15610205
21 rs2032257 27774870 3.97610205 5.39610205
22 rs1009147 30088257 8.41610205 4.51610205
22 rs1005239 47687170 9.86610205 8.67610205
*SNP not selected for replication because of strong linkage disequilibrium with another SNP.
doi:10.1371/journal.pone.0091621.t004
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17% per G allele to develop CMH in a population of ex- and
current heavy smokers.
Multivariate regression analysis, stratified for current an ex-
smoking, showed essentially the same effect sizes and direction of
the association of CMH and the risk allele of rs6577641. It is likely
that lack of power is the reason for not reaching the level of
significance in ex-smokers.
These data strongly suggest that SATB1 plays a role in the
susceptibility to CMH in subjects with a history of heavy smoking
($20 pack-years) within the general population. Moreover,
rs6577641 has a cis-eQTL effect on SATB1 lung tissue expression,
the risk allele at rs6577641 (G) increasing and the A-allele
reducing expression of SATB1 significantly. Additionally, we found
a higher SATB1 expression in bronchial biopsies of COPD-
patients with CMH. We found no differences between the GG and
AA genotypes for protein expression of SATB1 in airway
epithelium by IHC in a small sample from our lung tissue registry.
Finally, we demonstrate that SATB1 mRNA expression is induced
during mucociliary differentiation in ALI cultures of human
bronchial epithelial cells of 2 donors supporting our eQTL
findings. Interestingly, expression of the mucin gene MUC5AC was
also induced during this culture period, with a slightly delayed
kinetics compared to SATB1. Together these data strongly suggest
that SATB1 is induced during differentiation of bronchial epithelial
cells and affects chronic mucus hypersecretion.
The forest plot clearly shows that the effect of SNP rs6577641 is
lower in cohorts including COPD patients only (GLUCOLD,
Rucphen, COPDGene, ECLIPSE and Norway) than in the other
cohorts. Additional meta-analysis of COPD-cohorts and general
population based cohorts separately confirmed this (COPD
cohorts, combined p-value = 0.236, OR=1.07 and general
population based cohorts, combined p-value = 5.1861027,
OR=1.26). This suggests genetic heterogeneity of CMH in
subjects with and without COPD.
The SNP most significantly associated with CMH, rs6577641, is
located in an intron of SATB1. SATB1 is a transcription factor and
chromatin (re)organizer important for controlling the expression of
many genes in a tissue or cell-type specific fashion, for instance in
differentiating thymus T-cells [17] or differentiating skin kerati-
nocytes [18]. Expression of SATB1 has been observed in normal
human bronchial epithelial cells by immunohistochemistry and
lower levels were observed in non-small lung cancer cells [16]. In
our study, we also showed the presence of SATB1 in bronchial
epithelial cells by IHC staining of lung tissue. However, no
significant differences were found between patients homozygous
for the protective and risk alleles, for either specific SATB1
staining or for PAS staining, the latter specifically detecting mucus.
This inability to detect a genotype effect on protein staining may
Figure 3. Forest plot showing evidence of association for
rs6577641 with chronic mucus hypersecretion in the identifi-
cation and replication cohorts. Vertically left, the identification
cohort and the replication cohorts included in the meta-analysis. The
boxes represent the precision and the horizontal lines represent the
confidence intervals. The squares represent the pooled effect estimate
from the meta-analysis of all cohorts. The horizontal axis shows the
scale of the effects.
doi:10.1371/journal.pone.0091621.g003
Figure 4. Percentage of subjects with chronic mucus hypersecretion (CMH) within genotypes (AA, AG and GG) of rs6577641 in the
identification cohort (NELSON), and distributed among ex- and current smokers.
doi:10.1371/journal.pone.0091621.g004
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be due to lack of power, as we found a large variation in SATB1
and PAS protein expression in the relatively small number of lung
tissue samples. Other explanations include possible expression
regulation of SATB1 by smoke exposure which could be a
dynamic process not readily detected at the protein level by any
single-time point analysis such as IHC staining on lung biopsies.
Alternatively SATB1 expression levels may vary throughout the
lungs or the technique used here is not sensitive enough to detect
relatively small differences in protein levels. To further explore the
association of SATB1 protein and its underlying regulation, it
would be of interest to perform longitudinal investigations on lung
tissue samples of subjects with and without CMH, or time series of
in vitro cultured epithelial cells from donors with a specific genotype
and cigarette smoke exposure. This would also allow further
studies on epigenetic regulation with methylation, microRNA or
histone modifications.
The lack of association between the SATB1 protein and
rs6577641 might additionally be due to the location of mucus
positive cells in lung tissue. Mucus is produced both by goblet cells
and submucosal glands, which we did not investigate further.
Normal mucus consists of 97% water and 3% solids including 30%
mucins. In case of dysregulation of mucus production, the
concentration of solids in mucus may increase up to 15%. A
further step therefore could involve investigating mucins/proteins
present in mucus, e.g. MUC5AC is predominantly produced by
goblet cells in proximal airways and MUC5B by secretory cells
throughout the airways and by submucosal glands.
How does SATB1 expression contribute to CMH? SATB1 is
known to be a genome organizer, a tissue specific chromatin
remodeling protein with a property to modifying chromatin
architecture by formation of loops, allowing contact of condensed
genomic DNA to regulatory transcription proteins [19]. Thus
SATB1 can control gene expression of a series of target genes
located within a single locus at a specific chromosomal location
[20]. This has for instance been elegantly shown in case of
differentiating keratinocytes [18], where Satb1 expression regu-
lates genes located in the keratinocyte-specific loci, leading to
adaptation of a specific cell fate of the differentiating keratinocytes.
Similarly, a mechanism by which SATB1 could contribute to
CMH is the induction of a gene expression program during
differentiation of bronchial epithelial cells, leading to adaptation of
a cell fate specific for mucus producing cells in the submucosal
glands or a goblet cell phenotype in the bronchial epithelium.
Involvement of Satb1 in pneumocyte differentiation was previ-
ously observed by Baguma et al. in mice [21]. We observed
induction of SATB1 expression in bronchial epithelial cells
differentiating under ALI culture conditions. Further research will
need to test whether a specific gene expression profile is induced
by SATB1 expression in differentiating bronchial epithelial cells.
SATB1 is also highly expressed in thymocytes, but absent in
mature non-activated T cells [22]. Moreover, Satb1 has been
shown in mice to be essential for expression of Thelper2 (Th2) cells
important in the regulation of genes encoding interleukin 4, 5 and
13 [19]. In Satb1-deficient mice, development of thymocytes
stopped after the CD4+/CD8+ stage with deregulation of many
genes [23]. Conversely, in case of excessive SATB1-production an
excess of Th2 cells may be formed which all produce IL-13, which
may contribute to increased mucus production. Therefore, a
putative role of SATB1 in T-cells for the CMH phenotype should
not be disregarded.
Strength of our study is the fact that we were able to replicate
our findings in different populations, ranging from cohorts
consisting of individuals with severe airflow limitation to cohorts
mainly consisting of healthy smokers. There are some limitations,
e.g. the presence of CMH was not based on actual measurements
of the amount of sputum produced but based on questionnaires
that were not completely similar in all study cohorts. Underre-
porting of CMH occurs since those experiencing CMH become
accustomed to these symptoms, believing they are smoking related
or because they are embarrassed to admit to cough and sputum.
Table 7. Meta-analysis of the effect of rs6577641 on mRNA expression levels of SATB1 in the lung*.
Probe Gene
Symbol Affymetrix Probe ID Z-score Groningen Z-score Laval Z-score UBC
Z-Score Meta-
Analysis
p-value Meta-
Analysis
N=351 N=335 N=409
SATB1 100148784_TGI_at 22.28 20.08 21.62 22.29 0.022
SATB1 100150253_TGI_at 20.84 20.49 21.62 21.70 0.088
SATB1 100305926_TGI_at 22.81 21.38 21.46 23.26 0.001
*To assess the effect of the SNP rs6577641 on gene expression, a Kruskal-Wallis test was performed. This test generates a p-value, but does not give a direction of the
effect. To assess the direction of the effect, a Spearman’s correlation test was performed. Next, a Z-score was calculated for each center and a meta-analysis performed
for each of the three SATB1 probes across all centers. Finally, a meta-analysis for all three SATB1 probes was performed across all centers. This generated a Z-score of
25.87 and a corresponding p-value of 4.3*1029, indicating that the susceptibility G allele of the SNP rs6577641 increases SATB1 expression.
doi:10.1371/journal.pone.0091621.t007
Figure 5. Bronchial biopsy mRNA-expression levels of SATB1 in
COPD patients with chronic mucus hypersecretion (n=38)
compared to patients without chronic mucus hypersecretion
(n=39).
doi:10.1371/journal.pone.0091621.g005
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We demonstrated that SATB1 mRNA expression is induced
during mucociliary differentiation in ALI cultures of HBE cells in a
small dataset (n = 2). However, these data seem reliable as they are
supported by eQTL data from lung tissue. Despite this drawback,
we consistently found evidence for association of SATB1 with
CMH in the populations studied, showing the robustness of our
finding. Moreover, we corroborated this finding by functional
studies in lung tissue, airway wall biopsies of COPD patients and
epithelial cultures. More extensive research is needed to investigate
which factors induce SATB1 expression in airway epithelium.
In summary, we performed identification analyses and meta-
analyses using data from almost 7,000 participants to identify
genes involved in susceptibility for CMH. It is remarkable that we
found a genetic association for CMH given this phenotype is partly
subjectively determined and not well delineated. Moreover,
despite cohort differences to define CMH and severity of airflow
limitation, we found consistent effects of SNP rs6577641 on CMH.
This confirms that the CMH phenotype, despite the fact that it is
self-reported, is a robust phenotype irrespective of the presence or
absence of airflow limitation. The association of rs6577641 on
chromosome 3 at the SATB1 locus with CMH was supported by
functional studies including gene expression findings, demonstrat-
ing SATB1 to be associated with CMH.
Chronic mucus hypersecretion is a bothersome symptom for
many people, it increases in prevalence with aging and affects
quality of life, exacerbations of symptoms due to respiratory
infections and ultimately increases mortality. The involvement of
SATB1 in CMH offers opportunities to better understand the
process leading to CMH, and future development of tailored
medicines.
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